In Difficult Times For AAV Gene Therapies, AbbVie Boosts Regenxbio’s Ambitions
Wet AMD Is Challenging Target
While other gene therapy companies are scaling back plans or struggling to raise cash, Regenxbio is benefitting from AbbVie’s partnership in wet AMD.
You may also be interested in...
Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.
The California-based biotech is reducing its workforce to help finance a Phase II study of Ixo-vec, its eye gene therapy which has been blighted by safety concerns.
Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead